Melchert PW, Zhang Q, Mukhopadhyay S, Kanumuri SRR, McCurdy CR, Markowitz JS (2023)
An in vitro evaluation of kratom (Mitragyna speciosa) on the catalytic activity of carboxylesterase 1 (CES1)
Chemico-Biological Interactions

Markowitz JS, De Faria L, Zhang Q, Melchert PW, Frye RF, Klee BO, Qian Y (2022)
The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects
Med Cannabis Cannabinoids 5: 199

Melchert PW, Qian Y, Zhang Q, Klee BO, Xing C, Markowitz JS (2022)
In vitro inhibition of carboxylesterase 1 by Kava (Piper methysticum) Kavalactones
Chemico-Biological Interactions

Qian Y, Markowitz JS (2022)
Prediction of Carboxylesterase 1 (CES1)-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models
Drug Metabolism & Disposition: The Biological Fate of Chemicals

Qian Y, Melchert PW, Markowitz JS (2022)
Involvement of esterases in the pulmonary metabolism of beclomethasone dipropionate and the potential influence of cannabis use
Chemico-Biological Interactions

Zhang Q, Melchert PW, Markowitz JS (2022)
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir
Chemico-Biological Interactions 365: 110097

Shi J, Xiao J, Wang X, Jung SM, Bleske BE, Markowitz JS, Patrick KS, Zhu HJ (2021)
Plasma carboxylesterase 1 predicts methylphenidate exposure: a proof-of-concept study using plasma protein biomarker for hepatic drug metabolism
Clinical Pharmacology & Therapeutics

Qian Y, Markowitz JS (2020)
Natural Products as Modulators of CES1 Activity
Drug Metabolism & Disposition: The Biological Fate of Chemicals 48: 993

Qian Y, Gurley BJ, Markowitz JS (2019)
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
J Clin Psychopharmacol 39: 462

Qian Y, Wang X, Markowitz JS (2019)
In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites
Drug Metabolism & Disposition: The Biological Fate of Chemicals 47: 465

Qian Y, Gilliland TK, Markowitz JS (2019)
The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin
Chemico-Biological Interactions

Zhu HJ, Patrick KS, Straughn AB, Reeves OT, 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS (2017)
Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers
J Clin Psychopharmacol 37: 419

Zhu HJ, Langaee TY, Gong Y, Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Markowitz JS (2016)
CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril
European Journal of Clinical Pharmacology 72: 681

Wang X, Zhu HJ, Markowitz JS (2015)
Carboxylesterase 1-Mediated Drug-Drug Interactions between Clopidogrel and Simvastatin
Biol Pharm Bull 38: 292

Kristensen KE, Zhu HJ, Wang X, Gislason GH, Torp-Pedersen C, Rasmussen HB, Markowitz JS, Hansen PR (2014)
Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study
Clinical Pharmacology & Therapeutics 96: 713

Markowitz JS, Zhu HJ, Patrick KS (2013)
Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability
J Child Adolesc Psychopharmacol 23: 648

Zhu HJ, Markowitz JS (2013)
Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation
European Journal of Clinical Pharmacology 69: 733

Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS (2013)
Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation
Journal of Pharmacology & Experimental Therapeutics 344: 665

Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JS (2012)
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions
Pharm Res 29: 972

Zhu HJ, Brinda B, Froehlich TE, Markowitz JS (2012)
A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants
Pharmacogenet Genomics 22: 215

Zhu HJ, Patrick KS, Markowitz JS (2011)
Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: Application to human ethanol interactions
Journal of Chromatography B Analyt Technol Biomed Life Sciences 879: 783

Zhu HJ, Appel DI, Peterson YK, Wang Z, Markowitz JS (2010)
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions
Toxicology 270: 59

Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS (2009)
Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril
Biochemical Pharmacology 77: 1266

Zhu HJ, Markowitz JS (2009)
Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants
Drug Metabolism & Disposition: The Biological Fate of Chemicals 37: 264

Zhu HJ, Appel DI, Jiang Y, Markowitz JS (2009)
Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver
Drug Metabolism & Disposition: The Biological Fate of Chemicals 37: 1819

LeVasseur NL, Zhu HJ, Markowitz JS, DeVane CL, Patrick KS (2008)
Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping
Journal of Chromatography B Analyt Technol Biomed Life Sciences 862: 140

Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS (2008)
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis
American Journal of Human Genetics 82: 1241

Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL (2007)
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study
Schizophr Res 93: 131

Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL (2006)
Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder
Int J Neuropsychopharmacol 9: 603

Stahl SM, Markowitz JS, Papadopoulos G, Sadik K (2004)
Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease
Curr Med Res Opin 20: 517

Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos G (2003)
Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine
Sleep 26: 602

Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP, Owens SD, McGurk S, DeVane L, Risch SC (2003)
Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study
Neurocase 9: 274

Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G (2003)
Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community
J Clin Psychiatry 64: 466

Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J, George MS (2001)
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates
Neurocase 7: 105